- Halozyme Therapeutics Inc (NASDAQ:HALO) will acquire Antares Pharma Inc (NASDAQ:ATRS) for $5.60 per share, valuing Antares at approximately $960 million.
- The transaction is expected to be accretive to Halozyme's 2022 revenue and adjusted earnings and accelerate top-and bottom-line growth through 2027, with multiple growth drivers beyond 2027.
- Antares' suite of FDA-approved and partner products utilizing the Antares auto-injector technology have already demonstrated commercial success and are positioned for long-term growth. The launch of Tlando will leverage the existing testosterone commercial infrastructure.
- Related: Antares Pharma's Oral Testosterone Treatment Scores FDA Approval.
- Halozyme will finance the transaction using existing cash on hand and new sources of debt. As of 31 December, Halozyme held a cash balance of $740.9 million.
- After completing the transaction, Halozyme expects to maintain less than 3.5x net debt-to-EBITDA.
- The transaction is expected to close in the first half of 2022.
- Halozyme reaffirms its 2022 guidance and commitment to the three-year $750 million share repurchase program.
- Price Action: ATRS shares are up 48.4% at $5.55 during the premarket session on the last check Wednesday.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
Halozyme Buys Antares In $960M Deal To Create One Drug Delivery, Specialty Product Entity
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks